NL-OMON42150已完成2 期
A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing*s disease - CSOM230B2411
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion criteria for Group 1:
- •1. Adult patients with confirmed diagnosis of ACTH-dependent Cushing*s disease
- •2. Patients with de novo Cushing*s disease can be included only if they are not considered candidates for pituitary surgery
- •3. Male or female patients aged 18 years or greater
- •4. Karnofsky performance status * 60 (i.e. requires occasional assistance, but is able to care for most of their personal
- •5.Patients on medical treatment for Cushing*s disease the following washout periods must be completed before
- •screening assessments are performed
- •6.Patients have been on pasireotide in the past but discontinued
- •because of lack of efficacy are also allowed to enter Group 1. Patients treated with pasireotide subcutaneously must have been discontinued from the treatment for at least 4 weeks before
- •screening. Patients treated with pasireotide LAR must have been
- •discontinued from the treatment for at least 12 weeks before screening.
- •7. Patients who meet the any one of the following critieria:
- •* They are naive to pasireotide
- •* They have recieved pasireatide in the past and have been discontinued bcause of lack of efficacy (2 weeks for pasireotide subcutaneously and 12 weeks of washout prior to screening for patients treated with pasireotide LAR)
- •8.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, if they are using
- •highly effective methods of contraception during dosing and for 30 days after stopping study medication.
排除标准
- •1. Patients with compression of the optic chiasm causing any visual field defect that requires surgical intervention
- •2. Diabetic patients with poor glycemic control as evidenced by HbA1c>8%
- •3. Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF>450 ms in males, and >460 ms in females, hypokalemia, hypomagnesaemia, uncontrolled hypothyroidism, family history of long QT syndrome, or concomitant medications known to prolong QT interval.
- •4. Patients with clinically significant valvular disease.
- •5. Patients with Cushing*s syndrome due to ectopic ACTH secretion
- •6. Patients with hypercortisolism secondary to adrenal tumors or nodular (primary) bilateral adrenal hyperplasia
- •7. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute MI less than one year prior to study entry or clinically significant impairment in cardiovascular function
- •8. Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with ALT/AST > 2 X ULN, serum bilirubin > 2.0 X ULN
- •9. Patients with serum creatinine >2.0 X ULN
- •10. Patients with WBC <3 X 10e9/L; Hb 90% < LLN; PLT <100 X 10e9/L
- •11. Patients who have a known inherited syndrome as the cause for hormone over-secretion (i.e. Carney Complex, McCune-Albright syndrome, MEN-1)
- •12. Patients who are hypothyroid and not on adequate replacement therapy
- •13. Patients with symptomatic cholelithiasis
研究者
相似试验
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety ofpasireotide s.c. alone or in combination with cabergoline inpatients with Cushing’s diseaseCushing's diseaseEUCTR2013-002170-49-GRovartis Pharma Services AG128
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s diseaseEUCTR2013-002170-49-HUovartis Pharma Services AG64
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety ofpasireotide s.c. alone or in combination with cabergoline inpatients with Cushing’s diseaseCushing's diseaseEUCTR2013-002170-49-FRovartis Pharma Services AG128
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s diseaseCushing's diseaseMedDRA version: 18.1 Level: LLT Classification code 10011651 Term: Cushing's disease System Organ Class: 100000004860EUCTR2013-002170-49-NLovartis Pharma Services AG64
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's diseaseEUCTR2013-002170-49-DEovartis Pharma Services AG64